現在 JavaScriptが無効になっています。
Yahoo!ファイナンスのすべての機能を利用するためには、JavaScriptの設定を有効にしてください。
JavaScriptの設定を変更する方法はこちら。

NASDAQ

シアトル・ジェネティクス

SGEN

---

15分ディレイ株価
--:--
（現地時刻: --:--）

ポートフォリオに追加

シアトル・ジェネティクスの掲示板の投稿コメント詳細

投稿コメント一覧へ戻る

kaz*ヒト投与可能で一斉摘発ｗ

No.32017/8/1 7:58

>>2

Brentuximab vedotin is an antibody-drug conjugate or ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-positive tumor cells.

The drug is used in the treatment of lymphoma, a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. The Reed-Sternberg cell expresses CD30.

返信

投資の参考になりましたか？

返信コメント

kaz*ヒト投与可能で一斉摘発ｗ
No.42017/8/1 7:59
>>3
“This is one of several brentuximab vedotin regulatory milestones during 2017 towards our goal of expanding its availabilty globally to patients in need. We recently submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for brentuximab vedotin approval in cutaneous T-cell lymphoma based primarily on our phase III ALCANZA clinical trial, and we plan to submit a supplemental BLA to the FDA for brentuximab vedotin in frontline Hodgkin lymphoma based on the positive phase III ECHELON-1 clinical trial. We plan to follow up with submissions to Health Canada for indications in these settings,” Siegall added.

Brentuximab vedotin is currently not approved for use in Cutaneous T-Cell Lymphoma (CTCL) or frontline Hodgkin lymphoma.
返信
投資の参考になりましたか？

投稿コメント一覧へ戻る

【PR】堅調な伸びを続ける「米国株」について学ぼう！高配当などおすすめ銘柄や選び方は？ - マネックス証券 - Yahoo!ファイナンス